{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T13:12:44Z","timestamp":1724073164726},"reference-count":22,"publisher":"ALUNA","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wiad Lek"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:p>The aim: To assess the dynamics of serum levels of angiopoietin-2 and transforming growth factor-\u03b21 in patients with chronic hepatitis C (CHC) with concomitant nonalcoholic fatty liver disease (NAFLD) after successful DAAs. \nMaterials and methods: 82 patients with CHC were examined, of which 56 were diagnosed with NAFLD and increased body weight. Ang-2, TGF-\u03b21, leptin, adiponectin, and the degree of liver fibrosis were determined for all participants. The patients were divided into groups: 1 gr. (n=23) \u2013 CH\u0421 + increased body weight + hepatic steatosis, 2 gr. (n=33) \u2013 \u0421\u041d\u0421 + increased body weight + nonalcoholic steatohepatitis, 3rd gr. (n=26) \u2013 CHC. All patients received DAAs for 12 weeks. \nResults: From 82 patients F3-4 had 31 people, F1-2 \u2013 25, F0-1 \u2013 11, F0 -15 patients. F3-4 and steatosis S2-3 (p&lt;0.05) was more common in patients of 2 gr.. Serum Ang-2 levels were higher (p&lt;0.05) in patients of 2 gr. with F3-4, than in patients with F0-2. Fibrosis regression occurred more often in patients with 1 and 3 gr. with F1-2 than in patients 2 gr. and F3-4 and was accompanied by a decrease in Ang-2 and TGF-\u03b21 levels. \nConclusions: High levels of Ang-2 and TGF-\u03b21 are registered in patients with CHC+NAFLD, which correlate with the degree of liver fibrosis and significantly decrease after successful DAAs in patients with low initial stages of liver fibrosis and normal body weight.<\/jats:p>","DOI":"10.36740\/wlek202210113","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T19:30:48Z","timestamp":1670614248000},"page":"2392-2396","source":"Crossref","is-referenced-by-count":1,"title":["DYNAMICS OF FIBROTIC CHANGES IN THE LIVER AFTER THE SUCCESSFUL ERADICATION OF HEPATITIS C VIRUS IN PATIENTS WITH NAFLD"],"prefix":"10.36740","volume":"75","author":[{"given":"Mariya A.","family":"Derbak","sequence":"first","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nataliya V.","family":"Lizanets","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oksana T.","family":"Hanych","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olesya M.","family":"Horlenko","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna Y.","family":"Mashura","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serhii O.","family":"Boiko","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nad\u2019a","family":"Rozumykov\u00e1","sequence":"additional","affiliation":[{"name":"SLOVAK MEDICAL UNIVERSITY IN BRATISLAVA, BRATISLAVA, SLOVAKIA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22436","published-online":{"date-parts":[[2022]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. El-Shabrawi M.H., Kamal N.M., Mogahed E.A. et al. Perinatal transmis-sion of hepatitis C virus: an update. Arch Med Sci. 2020; 16(6):1360- 1369. doi: 10.5114\/aoms.2019. 83644.","DOI":"10.5114\/aoms.2019.83644"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Salomone F., Petta S., Micek A. et al. Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis. Liver Int. 2020;40(11):2820-2827. doi: 10.1111\/liv.14608.","DOI":"10.1111\/liv.14608"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Suda G., Sakamoto N. Recent advances in the treatment of hepatitis C virus infection for special populations and remaining problems. J Gastroenterol Hepatol. 2021;36(5):1152-1158. doi: 10.1111\/jgh.15189.","DOI":"10.1111\/jgh.15189"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Tachi Y., Hirai T., Miyata A. et al. Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response. Hepatol Res. 2015;45(2):238-46. doi: 10.1111\/ hepr.12331.","DOI":"10.1111\/hepr.12331"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Hern\u00e1ndez-Bartolom\u00e9 \u00c1., L\u00f3pez-Rodr\u00edguez R., Borque M.J. et al. Angiopoietin-2\/angiopoietin-1 as non-invasive biomarker of cirrhosis in chronic hepatitis C. World J Gastroenterol. 2016;22(44):9744-9751. doi: 10.3748\/wjg.v22.i44.9744.","DOI":"10.3748\/wjg.v22.i44.9744"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Che Noh I., Avoi R., Abdullah Nurul A. et al. Analysis of serum and gene expression profile of cytokines (IL-6, TNF-\u03b1 and TGF-\u03b21) in chronic hepatitis C virus infection. PeerJ. 2022;10:e13330. doi: 10.7717\/ peerj.13330.","DOI":"10.7717\/peerj.13330"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Isaac A., El Sakaty T.M., Hussein S.H. et al. Angiopoietin-2 as a predictor of fibrosis regression in chronic hepatitis C virus patients after direct-acting antiviral drugs. Egypt J Intern Med. 2021;33: 53. doi:10.1186\/ s43162-021-00086-5.","DOI":"10.1186\/s43162-021-00086-5"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Das S.K., Balakrishnan V. Role of cytokines in the pathogenesis of non-alcoholic Fatty liver disease. Indian J Clin Biochem. 2011;26(2):202-9. doi: 10.1007\/s12291-011-0121-7.","DOI":"10.1007\/s12291-011-0121-7"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Coulon S., Heindryckx F., Geerts A. et al. Angiogenesis in chronic liver disease and its complications. Liver Int. 2011;31(2):146-62. doi: 10.1111\/j.1478-3231.2010.02369.x.","DOI":"10.1111\/j.1478-3231.2010.02369.x"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Zadorozhna M., Di Gioia S., Conese M., Mangieri D. Neovascularization is a key feature of liver fibrosis progression: anti-angiogenesis as an innovative way of liver fibrosis treatment. Mol Biol Rep. 2020;47(3):2279-2288. doi: 10.1007\/s11033-020-05290-0.","DOI":"10.1007\/s11033-020-05290-0"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Dewidar B., Meyer C., Dooley S., Meindl-Beinker A.N. TGF-\u03b2 in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019. Cells. 2019;8(11):1419. doi: 10.3390\/cells8111419.","DOI":"10.3390\/cells8111419"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Van Meeteren L.A., Goumans M.J., ten Dijke P. TGF-\u03b2 receptor signaling pathways in angiogenesis; emerging targets for anti-angiogenesis therapy. Curr Pharm Biotechnol. 2011;12(12):2108-20. doi: 10.2174\/138920111798808338.","DOI":"10.2174\/138920111798808338"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Moon W.S., Rhyu K.H., Kang M.J. et al. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod Pathol. 2003;16(6):552-7. doi: 10.1097\/01. MP.0000071841.17900.69.","DOI":"10.1097\/01.mp.0000071841.17900.69"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Abd-El-Moety H.A., Magour G.H., Maharem D.A. et al. Evaluation of serum angiopoietin-II in HCV related glomerulonephritis. Alexandria J Med. 2011; 47:97-103.","DOI":"10.1016\/j.ajme.2011.07.008"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Eklund L., Olsen B.R. Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp Cell Res. 2006;312(5):630-41. doi: 10.1016\/j.yexcr.2005.09.002.","DOI":"10.1016\/j.yexcr.2005.09.002"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Mauro E., Crespo G., Montironi C. et al. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. Hepatology. 2018;67(5):1683-1694. doi: 10.1002\/hep.29557.","DOI":"10.1002\/hep.29557"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Van der Meer A.J., Maan R., Veldt B.J. et al. Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis. J Gastroenterol Hepatol. 2016;31(6):1168-76. doi: 10.1111\/jgh.13252.","DOI":"10.1111\/jgh.13252"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Makhlouf M.M., Osman M.A., Saleh S.A. et al. Serum angiopoietin-2 as a noninvasive diagnostic marker of stages of liver fbrosis in chronic hepatitis C patients. Egypt J Intern Med. 2016;28:140-148.","DOI":"10.4103\/1110-7782.203293"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19. Osawa Y., Yoshio S., Aoki Y. et al. Blood angiopoietin-2 predicts liver angiogenesis and fbrosis in hepatitis C patients. BMC Gastroenterol. 2021;21(1):55. doi:10.1186\/s12876-021-01633-8.","DOI":"10.1186\/s12876-021-01633-8"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Lefere S., Van de Velde F., Hoorens A. et al. Angiopoietin-2 Promotes Pathological Angiogenesis and Is a Therapeutic Target in Murine Nonalcoholic Fatty Liver Disease. Hepatology. 2019;69(3):1087-1104. doi: 10.1002\/hep.30294.","DOI":"10.1002\/hep.30294"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. She Y., Mangat R., Tsai S. et al. The Interplay of Obesity, Dyslipidemia and Immune Dysfunction: A Brief Overview on Pathophysiology, Animal Models, and Nutritional Modulation. Front Nutr. 2022;9:840209. doi: 10.3389\/fnut.2022.840209.","DOI":"10.3389\/fnut.2022.840209"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Radwan M.I., Pasha H.F., Mohamed R.H. et al. Influence of transforming growth factor-\u03b21 and tumor necrosis factor-\u03b1 genes polymorphisms on the development of cirrhosis and hepatocellular carcinoma in chronic hepatitis C patients. Cytokine. 2012;60(1):271-6. doi: 10.1016\/j. cyto.2012.05.010.","DOI":"10.1016\/j.cyto.2012.05.010"}],"container-title":["Wiadomo\u015bci Lekarskie"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T19:35:05Z","timestamp":1670614505000},"score":1,"resource":{"primary":{"URL":"https:\/\/wiadlek.pl\/wp-content\/uploads\/archive\/2022\/10\/WLek202210113.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":22,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022]]},"published-print":{"date-parts":[[2022,10]]}},"URL":"https:\/\/doi.org\/10.36740\/wlek202210113","archive":["Internet Archive"],"relation":{},"ISSN":["0043-5147"],"issn-type":[{"value":"0043-5147","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}